Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Complement protein C5 inhibitor
DRUG
2 trials
Sponsors
Tianjin Medical University General Hospital
Conditions
Neuromyelitis Optica Spectrum Disorder Attack
Phase 2
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Withdrawn
NCT06673394
Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorder Attack
Start: 2025-09-03
End: 2026-12-01
Updated: 2025-09-10
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Active, not recruiting
NCT07184840
Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorder Attack
Start: 2025-09-09
End: 2026-09-30
Updated: 2026-06-03